Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on N-formyl-methionyl-leucyl-phenylalanine-induced responses of polymorphonuclear neutrophils in vitro

Takatoshi Ito, Mitsuhiro Fujihara, Hideki Abe, Miki Yamaguchi, Shinobu Wakamoto, Shinji Takeoka, Hiromi Sakai, Eishun Tsuchida, Hisami Ikeda, Kenji Ikebuchi

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    [Poly(ethyleneglycol)]-modified hemoglobin vesicles (PEG-HbV), a type of encapsulated hemoglobin, have been developed as artificial oxygen carriers and it is important to evaluate their blood compatibility. We studied the effects of PEG-HbV on human polymorphonuclear neutrophils (PMNs) in vitro, focusing on the functional responses to N-formyl-methionyl-leucyl-phenylalanine (fMLP) as an agonist. The pretreatment of the PMNs with PEG-HbV up to a concentration of 60 mg/dl Hb did not affect the fMLP-triggered chemotactic activity. In parallel to these results, the fMLP-induced upregulation of CD11b (Mac-1) levels on the PEG-HbV-pretreated PMNs was comparable to that of untreated cells. Furthermore, the pretreatment of the PMNs with the PEG-HbV even at 600 mg/dl Hb did not affect the gelatinase B (Matrix methalloproteinase-9 (MMP-9)) release, suggesting that the fMLP-induced release of secondary and tertiary granules was normal. In addition, the fMLP-triggered superoxide production of the PMNs was unchanged by the pretreatment with the PEG-HbV at 600 mg/dl Hb. Thus, these results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on the fMLP-triggered functions of human PMNs.

    Original languageEnglish
    Pages (from-to)427-437
    Number of pages11
    JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
    Volume29
    Issue number6
    DOIs
    Publication statusPublished - 2001

    Fingerprint

    N-Formylmethionine Leucyl-Phenylalanine
    Hemoglobin
    methionyl-leucyl-phenylalanine
    Hemoglobins
    Neutrophils
    In Vitro Techniques
    Matrix Metalloproteinase 9
    Superoxides
    Blood
    Up-Regulation
    Oxygen

    ASJC Scopus subject areas

    • Biomedical Engineering
    • Hematology
    • Biotechnology
    • Biomaterials

    Cite this

    Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on N-formyl-methionyl-leucyl-phenylalanine-induced responses of polymorphonuclear neutrophils in vitro. / Ito, Takatoshi; Fujihara, Mitsuhiro; Abe, Hideki; Yamaguchi, Miki; Wakamoto, Shinobu; Takeoka, Shinji; Sakai, Hiromi; Tsuchida, Eishun; Ikeda, Hisami; Ikebuchi, Kenji.

    In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, Vol. 29, No. 6, 2001, p. 427-437.

    Research output: Contribution to journalArticle

    Ito, Takatoshi ; Fujihara, Mitsuhiro ; Abe, Hideki ; Yamaguchi, Miki ; Wakamoto, Shinobu ; Takeoka, Shinji ; Sakai, Hiromi ; Tsuchida, Eishun ; Ikeda, Hisami ; Ikebuchi, Kenji. / Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on N-formyl-methionyl-leucyl-phenylalanine-induced responses of polymorphonuclear neutrophils in vitro. In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 2001 ; Vol. 29, No. 6. pp. 427-437.
    @article{32ee78690eab4f5098e73e6f5a87dd7c,
    title = "Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on N-formyl-methionyl-leucyl-phenylalanine-induced responses of polymorphonuclear neutrophils in vitro",
    abstract = "[Poly(ethyleneglycol)]-modified hemoglobin vesicles (PEG-HbV), a type of encapsulated hemoglobin, have been developed as artificial oxygen carriers and it is important to evaluate their blood compatibility. We studied the effects of PEG-HbV on human polymorphonuclear neutrophils (PMNs) in vitro, focusing on the functional responses to N-formyl-methionyl-leucyl-phenylalanine (fMLP) as an agonist. The pretreatment of the PMNs with PEG-HbV up to a concentration of 60 mg/dl Hb did not affect the fMLP-triggered chemotactic activity. In parallel to these results, the fMLP-induced upregulation of CD11b (Mac-1) levels on the PEG-HbV-pretreated PMNs was comparable to that of untreated cells. Furthermore, the pretreatment of the PMNs with the PEG-HbV even at 600 mg/dl Hb did not affect the gelatinase B (Matrix methalloproteinase-9 (MMP-9)) release, suggesting that the fMLP-induced release of secondary and tertiary granules was normal. In addition, the fMLP-triggered superoxide production of the PMNs was unchanged by the pretreatment with the PEG-HbV at 600 mg/dl Hb. Thus, these results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on the fMLP-triggered functions of human PMNs.",
    author = "Takatoshi Ito and Mitsuhiro Fujihara and Hideki Abe and Miki Yamaguchi and Shinobu Wakamoto and Shinji Takeoka and Hiromi Sakai and Eishun Tsuchida and Hisami Ikeda and Kenji Ikebuchi",
    year = "2001",
    doi = "10.1081/BIO-100108548",
    language = "English",
    volume = "29",
    pages = "427--437",
    journal = "Artificial Cells, Nanomedicine and Biotechnology",
    issn = "2169-1401",
    publisher = "Informa Healthcare",
    number = "6",

    }

    TY - JOUR

    T1 - Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on N-formyl-methionyl-leucyl-phenylalanine-induced responses of polymorphonuclear neutrophils in vitro

    AU - Ito, Takatoshi

    AU - Fujihara, Mitsuhiro

    AU - Abe, Hideki

    AU - Yamaguchi, Miki

    AU - Wakamoto, Shinobu

    AU - Takeoka, Shinji

    AU - Sakai, Hiromi

    AU - Tsuchida, Eishun

    AU - Ikeda, Hisami

    AU - Ikebuchi, Kenji

    PY - 2001

    Y1 - 2001

    N2 - [Poly(ethyleneglycol)]-modified hemoglobin vesicles (PEG-HbV), a type of encapsulated hemoglobin, have been developed as artificial oxygen carriers and it is important to evaluate their blood compatibility. We studied the effects of PEG-HbV on human polymorphonuclear neutrophils (PMNs) in vitro, focusing on the functional responses to N-formyl-methionyl-leucyl-phenylalanine (fMLP) as an agonist. The pretreatment of the PMNs with PEG-HbV up to a concentration of 60 mg/dl Hb did not affect the fMLP-triggered chemotactic activity. In parallel to these results, the fMLP-induced upregulation of CD11b (Mac-1) levels on the PEG-HbV-pretreated PMNs was comparable to that of untreated cells. Furthermore, the pretreatment of the PMNs with the PEG-HbV even at 600 mg/dl Hb did not affect the gelatinase B (Matrix methalloproteinase-9 (MMP-9)) release, suggesting that the fMLP-induced release of secondary and tertiary granules was normal. In addition, the fMLP-triggered superoxide production of the PMNs was unchanged by the pretreatment with the PEG-HbV at 600 mg/dl Hb. Thus, these results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on the fMLP-triggered functions of human PMNs.

    AB - [Poly(ethyleneglycol)]-modified hemoglobin vesicles (PEG-HbV), a type of encapsulated hemoglobin, have been developed as artificial oxygen carriers and it is important to evaluate their blood compatibility. We studied the effects of PEG-HbV on human polymorphonuclear neutrophils (PMNs) in vitro, focusing on the functional responses to N-formyl-methionyl-leucyl-phenylalanine (fMLP) as an agonist. The pretreatment of the PMNs with PEG-HbV up to a concentration of 60 mg/dl Hb did not affect the fMLP-triggered chemotactic activity. In parallel to these results, the fMLP-induced upregulation of CD11b (Mac-1) levels on the PEG-HbV-pretreated PMNs was comparable to that of untreated cells. Furthermore, the pretreatment of the PMNs with the PEG-HbV even at 600 mg/dl Hb did not affect the gelatinase B (Matrix methalloproteinase-9 (MMP-9)) release, suggesting that the fMLP-induced release of secondary and tertiary granules was normal. In addition, the fMLP-triggered superoxide production of the PMNs was unchanged by the pretreatment with the PEG-HbV at 600 mg/dl Hb. Thus, these results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on the fMLP-triggered functions of human PMNs.

    UR - http://www.scopus.com/inward/record.url?scp=18244388252&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=18244388252&partnerID=8YFLogxK

    U2 - 10.1081/BIO-100108548

    DO - 10.1081/BIO-100108548

    M3 - Article

    C2 - 11795629

    AN - SCOPUS:18244388252

    VL - 29

    SP - 427

    EP - 437

    JO - Artificial Cells, Nanomedicine and Biotechnology

    JF - Artificial Cells, Nanomedicine and Biotechnology

    SN - 2169-1401

    IS - 6

    ER -